Skip to main content
Have a personal or library account? Click to login

References

  1. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006 Apr; 47( 8s1): C7C12.
  2. Mozaffarian D , Benjamin EJ , Go AS , Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133( 4): e38e360.
  3. Cooke JP. Flow, NO, and atherogenesis. Proc Natl Acad Sci U S A. 2003 Feb 4; 100( 3): 76870.
  4. Strong JP , Malcom GT , McMahan CA , Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999 Feb 24; 281( 8): 72735.
  5. Cartier A , Lemieux I , Alméras N , Tremblay A , Bergeron J , Després JP. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 2008 May; 93( 5): 19318.
  6. Abeywardena MY , Leifert WR , Warnes KE , Varghese JN , Head RJ. Cardiovascular biology of interleukin-6. Curr Pharm Des. 2009; 15( 15): 180921.
  7. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003 Aug 21; 92( 4B): 17K22K.
  8. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009 Sep; 94( 9): 317182.
  9. Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec 19–26; 420( 6917): 86874.
  10. Roman MJ , Shanker BA , Davis A , Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 Dec 18; 349( 25): 2399406.
  11. Anker SD von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004 Apr; 90( 4): 46470.
  12. Vallance P , Collier J , Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 1997 May 10; 349( 9062): 13912.
  13. Levi M , van der Poll T , Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004 Jun 8; 109( 22): 2698704.
  14. Wagner DD Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003 Dec; 23( 12): 21317.
  15. Skålén K , Gustafsson M , Rydberg EK , Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002 Jun 13; 417( 6890): 7504.
  16. Kones R Rumana U. Current treatment of dyslipidemia: evolving roles of non-statin and newer drugs. Drugs. 2015 Jul; 75( 11): 120128.
  17. Ansell BJ , Watson KE , Fogelman AM , Navab M , Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005 Nov 15; 46( 10): 17928.
  18. Esdaile JM , Abrahamowicz M , Grodzicky T , Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct; 44( 10): 23317.
  19. Krauss RM , Winston M , Fletcher BJ , Grundy SM. Obesity: impact on cardiovascular disease. Circulation. 1998 Oct 6; 98( 14): 147276.
  20. Goldstein JL , Ho YK , Basu SK , Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979 Jan; 76( 1): 3337.
  21. Libby P , Ridker PM , Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011 May 19; 473( 7347): 31725.
  22. Jun M , Foote C , Lv J , Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010 May 29; 375( 9729): 187584.
  23. Li S , Gokden N , Okusa MD , Bhatt R , Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol. 2005 Aug; 289( 2): F46980.
  24. Husain S , Andrews NP , Mulcahy D , Panza JA , Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998 Mar 3; 97( 8): 71620.
  25. Münzel T Keaney JF. Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation. 2001 Sep 25; 104( 13): 15714.
  26. Molinaro R , Wolfram J , Federico C , Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opin Drug Deliv. 2013 Dec; 10( 12): 165368.
  27. Chacko AM , Hood ED , Zern BJ , Muzykantov VR. Targeted nano-carriers for imaging and therapy of vascular inflammation. Curr Opin Colloid Interface Sci. 2011 Jun; 16( 3): 21527.
  28. Muzykantov VR. Targeted therapeutics and nanodevices for vascular drug delivery: quo vadis? IUBMB Life. 2011 Aug; 63( 8): 5835.
  29. Howard M , Zern BJ , Anselmo AC , Shuvaev VV , Mitragotri S , Muzykantov V. Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm. ACS Nano. 2014 May 27; 8( 5): 410032.
  30. Wagner DD Frenette PS. The vessel wall and its interactions. Blood. 2008 Jun 1; 111( 11): 527181.
  31. Ruiz-Esparza GU , Segura-Ibarra V , Cordero-Reyes AM , A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. Eur J Heart Fail. 2016 Feb; 18( 2): 16978.
  32. Yang H , Zhao F , Li Y , VCAM-1-targeted core/shell nanoparticles for selective adhesion and delivery to endothelial cells with lipopolysaccharide-induced inflammation under shear flow and cellular magnetic resonance imaging in vitro. Int J Nanomedicine. 2013; 8: 1897906.
  33. Robbins GP , Saunders RL , Haun JB , Rawson J , Therien MJ , Hammer DA. Tunable leuko-polymersomes that adhere specifically to inflammatory markers. Langmuir. 2010 Sep 7; 26( 17): 1408996.
  34. Li D , Patel AR , Klibanov AL , Molecular imaging of athero-sclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging. 2010 Jul; 3( 4): 46472.
  35. Homem de Bittencourt PI Jr , Lagranha DJ , Maslinkiewicz A , LipoCardium: endothelium-directed cyclopentenone prostaglan-din-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis. 2007 Aug; 193( 2): 24558.
  36. Cyrus T , Zhang H , Allen JS , Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol. 2008 May; 28( 5): 8206.
  37. Chorny M , Fishbein I , Yellen BB , Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A. 2010 May 4; 107( 18): 834651.
  38. Myerson J , He L , Lanza G , Tollefsen D , Wickline S. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J Thromb Haemost. 2011 Jul; 9( 7): 1292300.
  39. Yoo JW , Irvine DJ , Discher DE , Mitragotri S. Bio-inspired, bio-engineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011 Jul 1; 10( 7): 52135.
  40. Hu CM , Fang RH , Wang KC , Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015 Oct 1; 526( 7571): 11821.
  41. Parodi A , Quattrocchi N , van de Ven AL , Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013 Jan; 8( 1): 618.
  42. McMahon KM , Mutharasan RK , Tripathy S , Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 2011 Mar 9; 11( 3): 120814.
  43. Allijn IE , Leong W , Tang J , Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano. 2013 Nov 26; 7( 11): 976170.
  44. Zhang W , He H , Liu J , Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials. 2013 Jan; 34( 1): 30619.
  45. Molinaro R , Corbo C , Martinez JO , Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat Mater. 2016; doi: 10.1038/NMAT4644. In Press.
  46. Jain MK Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005 Dec; 4( 12): 97787.
Language: English
Page range: 169 - 174
Published on: Jul 1, 2016
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2016 Roberto Molinaro, Christian Boada, Guillermo Medrano del Rosal, Kelly A. Hartman, Claudia Corbo, Elizabeth D. Andrews, Naama E. Toledano-Furman, John P. Cooke, Ennio Tasciotti, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.